ICU sedation, delirium & recovery
Post-traumatic stress disorder and quality of life alterations in survivors of immune-mediated thrombotic thrombocytopenic purpura and atypical hemolytic and uremic syndrome
Study context
- Population
- Survivors of iTTP and atypical hemolytic-uremic syndrome (aHUS) in remission, interviewed 72 [48–84] months after ICU discharge
- Participants
- 103 survivors
- Exposure
- iTTP vs aHUS survivors; patients with vs without posttraumatic stress disorder (PTSD) symptoms
- iTTPn = 52
- aHUSn = 51
- Outcome
- Symptoms of anxiety, depression and PTSD, and quality of life (SF-36)
- Follow-up
- 72 [48-84] months after ICU discharge
Methodological detailstelephone interviews
- Telephone interviews
Main finding
As reported in the abstract
Symptoms of anxiety, PTSD and depression
Anxiety symptoms
50%
PTSD symptoms
27%
Depression symptoms
14%
Observational data: associations, not effects.
Further findings
Factors independently associated with PTSD symptoms
| OR (95% CI) | ||
|---|---|---|
| Male sex | 0.11 (0.02–0.53) | |
| Platelet count ≤20 G/L at acute-episode presentation | 2.68 (1.01–7.38) | |
| Current treatment | 2.69 (1.01–7.36) | |
| 0.050.21520Odds ratio (log scale) |
Characteristics of patients with PTSD symptoms
- Significantly greater weight gain and significantly worse perceived physical and/or emotional wellbeing, anxiety and depression symptoms in patients with PTSD symptoms
Quality of life (SF-36 physical and mental components)
- Significantly greater impairment in patients with vs without PTSD symptoms, and in aHUS with PTSD vs iTTP with or without PTSD
Quality of life, aHUS (subgroup)
- Significantly better with vs without eculizumab treatment
Original publication
Post-traumatic stress disorder and quality of life alterations in survivors of immune-mediated thrombotic thrombocytopenic purpura and atypical hemolytic and uremic syndrome. J Crit Care. Published 15 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →